High Blood Pressure After 50: What the Trials Show About Targets and Treatment

High blood pressure is common, it usually causes no symptoms, and treating it has been studied more thoroughly than almost anything else in medicine. Over the past two decades, several large randomized trials have asked two plain questions: how far down should blood pressure go, and which drugs should come first. The answers are clearer than most people assume, but they are not one-size-fits-all, and they come with real cautions once you pass 50 and especially past 75. This is a report on what those trials measured, not a set of instructions. Numbers here describe study populations, not you.

How high pressure earns its reputation

Blood pressure is written as two numbers. The top number, systolic, is the pressure while the heart beats. The bottom number, diastolic, is the pressure between beats. Both are measured in millimeters of mercury (mm Hg). In adults over 50, the systolic number tends to be the one that drives risk, because arteries stiffen with age and the top number keeps climbing.

The link between higher pressure and worse outcomes is one of the most consistent findings in cardiovascular research. Higher long-term pressure tracks with more strokes, heart attacks, heart failure, and kidney disease. What the trials below add is the harder question: does actively lowering pressure with medication change those outcomes, and by how much.

SPRINT: the case for a lower target

The Systolic Blood Pressure Intervention Trial, known as SPRINT, is the trial that reset the conversation. It enrolled 9,361 adults at increased cardiovascular risk who did not have diabetes or a prior stroke, and randomly assigned them to a systolic target below 120 or below 140 (SPRINT Research Group, NEJM, 2015).

The intensive group did better on the outcomes that matter. The primary composite endpoint (heart attack, acute coronary syndrome, stroke, heart failure, or cardiovascular death) occurred at about 1.65 percent per year in the intensive group versus about 2.19 percent per year in the standard group, roughly a 25 percent relative reduction. All-cause death fell by about 27 percent (1.06 versus 1.41 percent per year). The trial was stopped early because the benefit was clear. Put in absolute terms, about 61 participants had to be treated to the lower target to prevent one primary-outcome event over the roughly three years of the trial, and about 90 to prevent one death (SPRINT Research Group, NEJM, 2015).

The lower target was not free. The intensive group had more episodes of low blood pressure, fainting, electrolyte abnormalities, and signs of kidney injury on lab tests. The trial also measured pressure using an automated, seated, rest-based method that often reads lower than a rushed clinic cuff, which is one reason the 120 figure cannot be transplanted directly onto a hallway reading.

Older adults: SPRINT 75-plus and HYVET

A common worry is that aggressive treatment helps the middle-aged but harms the old. Two trials speak to that directly.

A prespecified SPRINT analysis looked only at the 2,636 participants aged 75 and older (Williamson et al., JAMA, 2016). The intensive target still reduced major cardiovascular events and all-cause death in this older group, including among participants judged to be frail or to walk slowly. Rates of serious adverse events tied to the treatment were not dramatically higher in the intensive arm in this analysis, though the absolute number of falls and low-pressure events remained a live concern for clinicians.

HYVET went older still, enrolling adults 80 and above with sustained high systolic pressure (Beckett et al., NEJM, 2008). It used a gentler target, around 150/80, with a thiazide-type diuretic (indapamide) with or without an ACE inhibitor (perindopril). Active treatment reduced all-cause death by about 21 percent and cut heart failure sharply. The reduction in total stroke, about 30 percent, did not reach statistical significance, which the authors reported plainly. The takeaway from HYVET is not a specific number to chase but the finding that treatment still offered benefit late in life.

Where intensive control did not win: ACCORD-BP

SPRINT is often quoted as if it settled the target for everyone. It did not, and the clearest counterweight is ACCORD-BP.

ACCORD-BP tested the same intensive systolic target, below 120 versus below 140, but in people with type 2 diabetes (ACCORD Study Group, NEJM, 2010). Here the intensive target did not significantly reduce the primary composite of nonfatal heart attack, nonfatal stroke, and cardiovascular death. Stroke, a secondary outcome, was reduced, but serious treatment-related adverse events were more common in the intensive group.

Two trials, similar targets, different populations, different headline results. That is the shape of the evidence, and it is why guideline writers treat diabetes, prior stroke, and frailty as reasons to individualize rather than to apply a single cutoff. That statement describes how the trials differ. It is not advice about what any one person should do.

Which drug first: ALLHAT and the drug classes

Choosing a target is one question. Choosing a starting drug is another, and ALLHAT remains the largest head-to-head trial on it.

ALLHAT randomized more than 33,000 older adults with high blood pressure to a thiazide-type diuretic (chlorthalidone), a calcium channel blocker (amlodipine), or an ACE inhibitor (lisinopril) (ALLHAT Officers, JAMA, 2002). For the primary outcome, fatal coronary heart disease and nonfatal heart attack, the three were essentially tied. The diuretic looked better than the comparators for preventing some secondary outcomes, notably heart failure, and it was inexpensive. The trial’s conclusion favored thiazide-type diuretics as a reasonable first step for many patients.

A quick map of the main classes, at the class level: thiazide-type diuretics help the kidneys shed sodium and water; ACE inhibitors and ARBs act on the renin-angiotensin system that constricts vessels and retains fluid, with ARBs often used when ACE inhibitors cause a cough; calcium channel blockers relax the vessel walls. Guidelines generally treat thiazide-type diuretics, ACE inhibitors, ARBs, and calcium channel blockers as acceptable first-line options, with the specific choice shaped by other conditions a person has. Which class fits a given person is a clinical decision, not something a trial summary can assign.

The thresholds shifted in 2017, and monitoring matters

In 2017 the American College of Cardiology and American Heart Association changed the numbers that define high blood pressure (Whelton et al., Hypertension, 2018). Normal was set below 120/80. Elevated was 120 to 129 systolic with diastolic under 80. Stage 1 hypertension became 130 to 139 systolic or 80 to 89 diastolic, and Stage 2 was 140/90 or higher. Lowering the label to 130/80 meant that, on paper, far more adults met the definition of hypertension, though for many the guideline emphasized lifestyle steps rather than immediate medication.

How pressure is measured turns out to matter as much as the target. A single cuff reading in a busy clinic can run high because of nerves or rushing. That is why home monitoring, using a validated upper-arm device and an average of several readings, has become a standard part of assessment (Shimbo et al., Circulation, 2020). The US Preventive Services Task Force recommends screening adults for high blood pressure and confirming it with measurements taken outside the clinic before starting treatment (US Preventive Services Task Force, JAMA, 2021).

The real cautions after 50

The trials that show benefit also document the costs of pushing pressure down, and those costs land harder with age.

Orthostatic drops and falls. Lowering blood pressure can cause it to fall too far on standing, producing lightheadedness that raises the risk of falls. This is a recurring concern in older participants across the intensive-treatment trials.

Kidney and electrolyte changes. SPRINT’s intensive group showed more laboratory signs of kidney strain and more electrolyte abnormalities, which is why blood tests are part of monitoring when medications are adjusted (SPRINT Research Group, NEJM, 2015). Diuretics in particular can move sodium and potassium levels.

Follow-up is not optional. The long-term SPRINT report continued to support the cardiovascular benefit of the lower target over extended follow-up while confirming the same adverse-event signals (SPRINT Research Group, NEJM, 2021). The pattern across trials is consistent: benefit and harm both scale with how aggressively pressure is lowered, so the balance depends heavily on the individual.

This article reports what randomized trials and major guidelines have found. It is not medical advice, and none of the targets, drug classes, or numbers above are a recommendation for any specific person. Blood pressure treatment depends on your age, your other conditions, how your pressure is measured, and how you tolerate medication. Those judgments belong with your own clinician, who can weigh the evidence here against your situation.

Common questions

Does the SPRINT target of 120 mean my home monitor should read under 120?

Not directly. SPRINT measured pressure with an automated device after several minutes of seated rest, a method that often reads lower than a quick clinic or home reading. The trial reported a benefit for its measured target in a specific high-risk group without diabetes or prior stroke. Translating that into a home number for an individual is a clinical decision, and the trials themselves do not provide a universal home cutoff.

If SPRINT showed a benefit, why did ACCORD-BP not?

They studied different people. SPRINT enrolled high-risk adults without diabetes, while ACCORD-BP enrolled people with type 2 diabetes, and the intensive target did not significantly reduce ACCORD-BP’s primary endpoint (ACCORD Study Group, NEJM, 2010). The contrast is a reminder that a result in one population does not automatically carry over to another.

Is one blood pressure drug clearly the best to start with?

No single class was a clear winner in ALLHAT, the largest head-to-head trial (ALLHAT Officers, JAMA, 2002). Thiazide-type diuretics, ACE inhibitors, ARBs, and calcium channel blockers are all treated as acceptable first-line options in guidelines. Diuretics performed at least as well as the newer classes and were cheap, but the right choice depends on a person’s other conditions.

Is treating high blood pressure worth it after age 80?

HYVET, which enrolled adults 80 and older, found that active treatment reduced all-cause death and heart failure using a gentler target than SPRINT (Beckett et al., NEJM, 2008). Benefit did not disappear with age. The cautions around low-pressure episodes, falls, and kidney monitoring, however, become more important the older and frailer a person is.